

Stephen D Ryder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2226657/publications.pdf>

Version: 2024-02-01

99
papers

8,538
citations

126907

33
h-index

49909

87
g-index

100
all docs

100
docs citations

100
times ranked

9835
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study. <i>Alcohol and Alcoholism</i> , 2022, 57, 203-210.	1.6	8
2	Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?. <i>Biomedicines</i> , 2022, 10, 477.	3.2	4
3	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	8.1	237
4	Characteristics of alcohol recovery narratives: Systematic review and narrative synthesis. <i>PLoS ONE</i> , 2022, 17, e0268034.	2.5	3
5	Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 215, 19-29.	1.7	4
6	The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study. <i>EBioMedicine</i> , 2022, 80, 104068.	6.1	3
7	Alcohol-related liver disease mortality and missed opportunities in secondary care: A United Kingdom retrospective observational study. <i>Drug and Alcohol Review</i> , 2022, 41, 1331-1340.	2.1	4
8	Persistent Hepatitis E virus infection across England and Wales 2009-2017: Demography, virology and outcomes. <i>Journal of Viral Hepatitis</i> , 2021, 28, 420-430.	2.0	12
9	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
10	The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. <i>Liver International</i> , 2021, 41, 934-948.	3.9	18
11	A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2021, 384, 808-817.	27.0	181
12	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. <i>European Journal of Health Economics</i> , 2021, 22, 505-518.	2.8	16
13	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	3.9	76
14	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , 2021, 6, 93.	1.8	1
15	Reply to Smith <i>et al.</i> Regarding "Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review with Meta-Analysis"™. <i>Alcohol and Alcoholism</i> , 2021, 56, 626-627.	1.6	0
16	New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK. <i>Lancet, The</i> , 2021, 397, 1770-1780.	13.7	18
17	Engagement with community liver disease management across the UK: a cross-sectional survey. <i>BJGP Open</i> , 2021, 5, BJGPO.2021.0085.	1.8	6
18	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , 2021, 6, 93.	1.8	7

#	ARTICLE	IF	CITATIONS
19	How to interpret and manage abnormal liver blood test results in older people. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-8.	0.5	3
20	Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial. American Journal of Gastroenterology, 2021, 116, 2292-2295.	0.4	12
21	Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to home. Clinical Medicine, 2021, 21, e32-e38.	1.9	4
22	Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review With Meta-analysis. Alcohol and Alcoholism, 2021, 56, 185-200.	1.6	22
23	Mapping of population disparities in the cholangiocarcinoma urinary metabolome. Scientific Reports, 2021, 11, 21286.	3.3	2
24	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-90.	0.7	0
25	Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD)? protocol for a feasibility randomised controlled trial. BMJ Open, 2021, 11, e054954.	1.9	6
26	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort. Journal of Clinical and Experimental Hepatology, 2020, 10, 17-29.	0.9	12
27	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1170-1178.e6.	4.4	61
28	Commentary: elastography as a predictor of portal hypertension. Alimentary Pharmacology and Therapeutics, 2020, 51, 204-205.	3.7	1
29	Will the COVID-19 pandemic affect HCV disease burden?. Digestive and Liver Disease, 2020, 52, 947-949.	0.9	15
30	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
31	Home based care pathway for the stratified treatment of HCV infection. Journal of Hepatology, 2020, 73, S22-S23.	3.7	0
32	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2020, 52, 500-512.	3.7	9
33	Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection. Journal of Medical Virology, 2020, 92, 3403-3411.	5.0	14
34	ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be Established. American Journal of Gastroenterology, 2019, 114, 175-176.	0.4	6
35	Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 442-453.	3.7	48
36	FRI-033-Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 70, e398.	3.7	0

#	ARTICLE	IF	CITATIONS
37	The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. <i>Addiction</i> , 2019, 114, 1113-1122.	3.3	33
38	Sofosbuvir/velpatasvir for 12-weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 71, 660-665.	3.7	93
39	<p>Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population</p>. <i>Hepatic Medicine: Evidence and Research</i> , 2019, Volume 11, 47-67.	2.5	10
40	PTU-009–Long-term effects of obeticholic acid in patients with primary biliary cholangitis on inflammatory markers. , 2019, , .		0
41	ATU-09–Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis. , 2019, , .		0
42	Glecaprevir/Pibrentasvir in patients with chronic <sc>HCV</sc> genotype 3 infection: An integrated phase 2/3 analysis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 337-349.	2.0	32
43	Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. <i>European Radiology</i> , 2019, 29, 3100-3107.	4.5	11
44	Reply to: “The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode”. <i>Journal of Hepatology</i> , 2018, 68, 1332.	3.7	0
45	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , 2018, 67, 2113-2126.	7.3	22
46	NI–0801, an anti–chemokine (C– motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. <i>Hepatology Communications</i> , 2018, 2, 492-503.	4.3	35
47	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
48	Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross–sectional study using transient elastography. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 504-515.	3.7	49
49	Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 68, 511-518.	3.7	73
50	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 951-960.	3.7	34
51	Risk-stratified screening for chronic liver disease using vibration-controlled transient elastography (Fibroscan). <i>Gastrointestinal Nursing</i> , 2018, 16, S15-S22.	0.1	3
52	IDDF2018-ABS-0107–Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). , 2018, , .		1
53	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	8.1	103
54	Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 1200-1201.	3.7	21

#	ARTICLE	IF	CITATIONS
55	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
56	The impact of rifaximin on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). <i>Frontline Gastroenterology</i> , 2017, 8, 243-251.	1.8	26
57	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
58	In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. <i>Gastroenterology</i> , 2017, 152, 1068-1077.e4.	1.3	141
59	New metrics for the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2017, 389, 2053-2080.	13.7	33
60	Screening for hepatocellular carcinoma: patient selection and perspectives. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 71-79.	3.7	27
61	Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 123-130.	3.7	8
62	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. <i>Journal of Clinical and Experimental Hepatology</i> , 2016, 6, 186-194.	0.9	13
63	The hepatitis C revolution part 1. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 563-571.	3.1	17
64	The hepatitis C revolution part 2. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 572-575.	3.1	0
65	Implementation of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2015, 386, 2098-2111.	13.7	76
66	Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2015, 62, 533-540.	3.7	161
67	Prednisolone or Pentoxifylline for Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2015, 372, 1619-1628.	27.0	602
68	Chronic hepatitis C – what do the new drugs offer and who should get them first?. <i>Clinical Medicine</i> , 2015, 15, 197-200.	1.9	5
69	Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. <i>BMJ Open</i> , 2015, 5, e007516-e007516.	1.9	86
70	The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2-factorial randomised controlled trial. <i>Health Technology Assessment</i> , 2015, 19, 1-104.	2.8	34
71	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. <i>Lancet, The</i> , 2014, 384, 1953-1997.	13.7	492
72	Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 262.	1.6	62

#	ARTICLE	IF	CITATIONS
73	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013, 57, 103-111.	7.3	103
74	The performance of transient elastography compared to clinical acumen and routine tests – what is the incremental diagnostic value?. <i>Liver International</i> , 2013, 33, 172-179.	3.9	7
75	The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call. <i>Clinical Infectious Diseases</i> , 2013, 56, 951-960.	5.8	35
76	Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 201-207.	1.6	14
77	Hepatitis B virus part 2: treatment options and the role of the specialist nurse. <i>Gastrointestinal Nursing</i> , 2013, 11, 33-40.	0.1	0
78	The Utility of Scoring Systems in Predicting Early and Late Mortality in Alcoholic Hepatitis: Whose Score Is It Anyway?. <i>International Journal of Hepatology</i> , 2012, 2012, 1-5.	1.1	24
79	Getting involved in clinical trials research in the UK: how can Clinical Research Networks help?. <i>Frontline Gastroenterology</i> , 2012, 3, 66-71.	1.8	2
80	Randomized clinical trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 543-550.	1.6	6
81	The Utility of Liver Function Tests for Mortality Prediction within One Year in Primary Care Using the Algorithm for Liver Function Investigations (ALFI). <i>PLoS ONE</i> , 2012, 7, e50965.	2.5	12
82	Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. <i>Journal of Clinical Pathology</i> , 2010, 63, 790-795.	2.0	51
83	Health outcomes following liver function testing in primary care: a retrospective cohort study. <i>Family Practice</i> , 2009, 26, 251-259.	1.9	23
84	Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 171-180.	0.5	41
85	Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2008, 135, 1176-1184.	1.3	636
86	Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. <i>British Journal of Cancer</i> , 2008, 98, 1166-1175.	6.4	121
87	Do high lipids help clearance of hepatitis C?. <i>Gut</i> , 2007, 56, 1044-1045.	12.1	3
88	The natural history of hepatitis C with severe hepatic fibrosis. <i>Journal of Hepatology</i> , 2007, 47, 37-45.	3.7	45
89	Outcome of hepatitis C infection: Bleak or benign?. <i>Journal of Hepatology</i> , 2007, 47, 4-6.	3.7	10
90	Mannan binding lectin and viral hepatitis. <i>Immunology Letters</i> , 2007, 108, 34-44.	2.5	62

#	ARTICLE	IF	CITATIONS
91	Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE). BMC Health Services Research, 2007, 7, 54.	2.2	13
92	Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease. European Journal of Gastroenterology and Hepatology, 2006, 18, 343-347.	1.6	0
93	Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. Journal of Hepatology, 2004, 41, 685-686.	3.7	88
94	Magnetic resonance cholangiopancreatography versus endoscopic retrograde cholangiopancreatography in the diagnosis of choledocholithiasis. European Journal of Gastroenterology and Hepatology, 2003, 15, 809-813.	1.6	11
95	Alcohol-related liver disease. Practitioner, 2003, 247, 414-7.	0.3	1
96	Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. Journal of Hepatology, 2001, 35, 195-199.	3.7	300
97	Directex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. European Journal of Immunology, 2001, 31, 2388-2394.	2.9	118
98	Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. Journal of Hepatology, 2000, 33, 371-375.	3.7	197
99	The Effect of Lectins on Crypt Cell Proliferation in Organ Culture. , 1998, 9, 475-482.		0